Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 9/20 | 0.38 |
| ▸ | EDNRA | P25101 | 8/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7841944 | 0.76 | TSHR (0.40) | TSHREDNRBEDNRACYP19A1MAPK1 | |
| SCHEMBL6289722 | 0.73 | HTR2A (0.38) | TSHREDNRBEDNRALMNAMAPT | |
| SCHEMBL6293272 | 0.72 | EDNRB (0.40) | EDNRBEDNRACYP19A1LMNAMAPT | |
| SCHEMBL6289705 | 0.65 | CYP19A1 (0.49) | TSHREDNRBEDNRACYP19A1MAPK1 | |
| SCHEMBL7216623 | 0.64 | CYP19A1 (0.42) | EDNRBEDNRACYP19A1LMNAMAPT | |
| SCHEMBL20610727 | 0.63 | CYP3A4 (0.75) | TSHREDNRAMAPTALDH1A1 | |
| SCHEMBL6289616 | 0.62 | CYP19A1 (0.42) | TSHREDNRBEDNRACYP19A1MAPT | |
| SCHEMBL6289234 | 0.61 | RIPK2 (0.44) | TSHREDNRBEDNRAMAPTMAPK1 | |
| SCHEMBL6292691 | 0.61 | PIK3CD (0.43) | TSHREDNRBEDNRALMNAMAPT | |
| SCHEMBL4631570 | 0.60 | CYP3A4 (0.72) | TSHRLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6962923-B2 | Pyrazole compositions | PFIZER INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20030232848-A1 | Pyrazole compositions | PFIZER INC. | 2003-12-18 | — | — | US | disclosed |
| US-6573270-B1 | Endothelin receptor antagonists | PFIZER INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1072597-A1 | Pyrazoles and their use as endothelin antagonists | Pfizer Limited (GB) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232848-A1 | Pyrazole compositions | EDNRB, EDNRA, AGTR1 | TSHR 645/4885EDNRB 1/4885EDNRA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.